Portal hypertension is a series of clinical manifestations caused by elevated pressure in the portal venous system, a clinical condition that is a combination of clinical manifestations of impaired portal blood circulation due to various causes. As the most serious clinical manifestation, ruptured esophagogastric fundic variceal bleeding threatens the life of patients with a first bleeding mortality rate of 40% to 85% as a nightmare. Although the current treatment for ruptured esophagogastric variceal bleeding has saved many patients’ lives in clinical treatment, there are still many problems to be solved: the success rate of hemostasis is low with drug treatment; surgical treatment is traumatic, slow recovery and high treatment risk; endoscopic sclerotherapy combined with ligation has a good success rate of hemostasis for ruptured esophageal variceal bleeding, but not for gastric fundic varices, however, it does not help. As a temporary hemostatic measure, it is unable to radically reduce portal vein pressure and therefore has a relatively high rebleeding rate. Once a patient has rebleeding, the financial pressure of treatment increases and the mortality rate of rebleeding is extremely high. Faced with such a difficult treatment situation, the medical team led by Prof. Wu Sex Jiang, Deputy Director of the General Surgery Department of Nanjing General Hospital of Nanjing Military Region and Chief Physician of the Institute of General Surgery of the Chinese PLA, under the guidance of Dr. Li Jieshou, a famous general surgeon, has repeatedly practiced and innovated a set of techniques based on transjugular intrahepatic portosystemic shunt (TIPS) as the core of the technique, combined with drug therapy. The medical team led by the famous general surgeon, Dr. Lai Jie-shou, has repeatedly practiced and innovated, and developed a comprehensive treatment model based on transjugular intrahepatic portosystemic shunt (TIPS) as the core technology, combined with drug treatment, surgical treatment and ICU life support technology. Relying on the National Institute of General Surgery, the hospital provides multidisciplinary treatment for patients through the integration of high-quality medical resources by combining imaging, intervention and other related departments. This technology has been carried out in our hospital for more than 20 years and has successfully treated more than 500 cases of portal hypertension patients with cirrhosis, Buga syndrome and other types of portal hypertension by taking advantage of its small trauma, good hemostatic effect and low rebleeding rate. The road is as long as iron, and now we step forward from the beginning. The medical team led by Prof. Wu continues to explore and improve the surgical methods. We have used the overlapping stent combined with bare stent to establish the shunt to improve the long-term patency rate; we have used the shunt recanalization technology to break through the dilemma of long-term shunt stenosis; we have used the parallel stent technology to solve the problem of shunt obstruction. This series of work experience has also been published in several international and domestic authoritative journals and has been recognized by domestic and international colleagues.